Statement: CCCEU Opposes EU's Discriminatory IPI Action Against Chinese Companies

June 20, 2025, Brussels

On 20 June 2025, the European Commission announced the exclusion of Chinese companies from participating in EU public procurement of medical devices exceeding €5 million, following its investigation under the International Procurement Instrument (IPI). It also imposed a cap, limiting the share of Chinese-origin products and components in awarded contracts to no more than 50%. The China Chamber of Commerce to the EU (CCCEU) expresses deep dissatisfaction and strongly opposes these unilateral and discriminatory measures taken by the EU.

The CCCEU considers the IPI findings neither impartial nor based on objective facts. The claim that most EU products and suppliers face discriminatory treatment in China’s public procurement market does not reflect reality. 

China and the EU have long maintained exchanges on issues related to the WTO Agreement on Government Procurement (GPA) and public procurement practices. Against this backdrop, the EU’s rushed adoption of unilateral measures is deeply disappointing to the business community.

The decision to exclude Chinese firms and impose localisation requirements is a blatant act of discrimination against Chinese products and suppliers in the EU’s medical public procurement sector. It seriously distorts fair competition and undermines the principle of a level playing field.

We urge the EU to take steps to reverse this regrettable decision and restore a fair, equitable, and non-discriminatory business environment for Chinese enterprises operating in the EU.